Insider Transactions in Q3 2025 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,402
-13.2%
|
$59,422
$11.03 P/Share
|
|
Jul 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,308
-5.87%
|
$51,696
$12.01 P/Share
|
|
Jul 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,815
+4.11%
|
-
|
|
Jul 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,841
-8.03%
|
$46,092
$12.01 P/Share
|
|
Jul 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,532
+5.66%
|
-
|
|
Jul 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,304
-9.52%
|
$51,648
$12.01 P/Share
|
|
Jul 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+6.58%
|
-
|